TY - JOUR
T1 - Influence of next-generation artificial intelligence on headache research, diagnosis and treatment
T2 - the junior editorial board members’ vision – part 2
AU - Petrušić, Igor
AU - Chiang, Chia Chun
AU - Garcia-Azorin, David
AU - Ha, Woo Seok
AU - Ornello, Raffaele
AU - Pellesi, Lanfranco
AU - Rubio-Beltrán, Eloisa
AU - Ruscheweyh, Ruth
AU - Waliszewska-Prosół, Marta
AU - Wells-Gatnik, William
PY - 2025/12
Y1 - 2025/12
N2 - Part 2 explores the transformative potential of artificial intelligence (AI) in addressing the complexities of headache disorders through innovative approaches, including digital twin models, wearable healthcare technologies and biosensors, and AI-driven drug discovery. Digital twins, as dynamic digital representations of patients, offer opportunities for personalized headache management by integrating diverse datasets such as neuroimaging, multiomics, and wearable sensor data to advance headache research, optimize treatment, and enable virtual trials. In addition, AI-driven wearable devices equipped with next-generation biosensors combined with multi-agent chatbots could enable real-time physiological and biochemical monitoring, diagnosing, facilitating early headache attack forecasting and prevention, disease tracking, and personalized interventions. Furthermore, AI-driven advances in drug discovery leverage machine learning and generative AI to accelerate the identification of novel therapeutic targets and optimize treatment strategies for migraine and other headache disorders. Despite these advances, challenges such as data standardization, model explainability, and ethical considerations remain pivotal. Collaborative efforts between clinicians, biomedical and biotechnological engineers, AI scientists, legal representatives and bioethics experts are essential to overcoming these barriers and unlocking AI’s full potential in transforming headache research and healthcare. This is a call to action in proposing novel frameworks for integrating AI-based technologies into headache care.
AB - Part 2 explores the transformative potential of artificial intelligence (AI) in addressing the complexities of headache disorders through innovative approaches, including digital twin models, wearable healthcare technologies and biosensors, and AI-driven drug discovery. Digital twins, as dynamic digital representations of patients, offer opportunities for personalized headache management by integrating diverse datasets such as neuroimaging, multiomics, and wearable sensor data to advance headache research, optimize treatment, and enable virtual trials. In addition, AI-driven wearable devices equipped with next-generation biosensors combined with multi-agent chatbots could enable real-time physiological and biochemical monitoring, diagnosing, facilitating early headache attack forecasting and prevention, disease tracking, and personalized interventions. Furthermore, AI-driven advances in drug discovery leverage machine learning and generative AI to accelerate the identification of novel therapeutic targets and optimize treatment strategies for migraine and other headache disorders. Despite these advances, challenges such as data standardization, model explainability, and ethical considerations remain pivotal. Collaborative efforts between clinicians, biomedical and biotechnological engineers, AI scientists, legal representatives and bioethics experts are essential to overcoming these barriers and unlocking AI’s full potential in transforming headache research and healthcare. This is a call to action in proposing novel frameworks for integrating AI-based technologies into headache care.
KW - Biosensors
KW - Chatbot
KW - Digital twin
KW - Drug discovery
KW - Machine learning
KW - Migraine
KW - Wearable devices
U2 - 10.1186/s10194-024-01944-7
DO - 10.1186/s10194-024-01944-7
M3 - Journal article
C2 - 39748331
AN - SCOPUS:85213985991
SN - 1129-2369
VL - 26
JO - Journal of Headache and Pain
JF - Journal of Headache and Pain
IS - 1
M1 - 2
ER -